

The Pharmacotherapy of Panic Disorder

Mark H. Pollack, M.D.

Panic disorder is common and associated with significant morbidity and dysfunction. The pharmacologic treatment of panic disorder is aimed at reducing or eliminating panic attacks, avoidance behavior, anticipatory anxiety, and comorbid conditions—and substantially improving and normalizing overall function and quality of life. Antidepressants and benzodiazepines remain the current mainstays of pharmacotherapy for panic disorder, although other novel agents and strategies are becoming available and may add effective alternatives to the therapeutic armamentarium.

(J Clin Psychiatry 2005;66[suppl 4]:23–27)

Panic disorder is common, with a lifetime prevalence of 3.5%, according to the National Comorbidity Survey.¹ It is diagnosed in a 3:1 female-to-male ratio in patients with agoraphobia and a 2:1 ratio in patients without agoraphobia. Panic disorder has an average age at onset in the third decade of life, although, consistent with the relatively earlier age at onset of anxiety disorders in general, over half of adult patients report significant difficulties with anxiety during childhood.² Panic disorder may have a seemingly spontaneous onset, although many individuals identify a life stressor occurring prior to the onset of panic symptoms; however, once initiated, the disorder may have a persistent course even in the absence of the continuous presence of the precipitating stressor.³

Panic disorder is associated with significant physical, mental, social, and vocational dysfunction, as well as diminished quality of life, comparable to that of patients with chronic medical conditions or depression.⁴ The dysfunction is greater in patients with comorbid mood or anxiety disorders. Although associated with excessive utilization of medical services^{5,6} and perhaps increased risk of death from cardiovascular causes,^{7,8} panic disorder may be unrecognized and untreated in half of affected patients in primary care settings^{9,10} because of its predominantly somatic rather than psychological symptom presentation, particularly in medical settings.^{11,12} Sym-

ptomatic and functional improvement, decreased utilization of medical resources, and reduction in overall costs are associated with treatment of panic in general medical settings.¹³ Pharmacotherapy of panic disorder may also normalize the decreased heart rate variability that may be a risk factor underlying panic-related cardiac death, and thus may, although unproven at present, reduce associated mortality.^{14,15}

TREATMENT CONSIDERATIONS

The goals for the treatment of panic disorder are to significantly reduce or eliminate panic attacks, avoidance behavior, anticipatory anxiety, and comorbid conditions and to substantially improve and normalize overall function and quality of life. Although this article will focus on pharmacologic treatment, both pharmacotherapy and cognitive-behavioral therapy have demonstrated efficacy for panic disorder in well-controlled clinical studies.

Development of an optimal treatment plan for an individual patient should include consideration of the patient's preference, particularly in the context of a review of the risks and benefits of each therapeutic intervention. In addition, the acuity of the distress and presence of significant comorbidities may help guide treatment selection; for instance, patients requiring rapid anxiolysis may require administration of benzodiazepines, whereas the presence of comorbid depression or substance abuse makes the case for administration of an antidepressant.

ANTIDEPRESSANTS


Antidepressants are often used as first-line treatments of anxiety disorders, including panic, because of their broad spectrum of efficacy against common comorbidities, especially depression, and the lack of the associated abuse and dependency liabilities that are associated with benzodiazepine administration.

From the Center for Anxiety and Traumatic Stress Related Disorders, Massachusetts General Hospital, Harvard Medical School, Boston, Mass.

This article is derived from the roundtable conference "New Insights Into the Nature and Treatment of Panic Disorder," which was held January 23, 2004, in Boston, Mass., and supported by an unrestricted educational grant from Forest Laboratories, Inc.

Corresponding author and reprints: Mark H. Pollack, M.D., Center for Anxiety and Traumatic Stress Related Disorders, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, WAC-815, Boston, MA 02114 (e-mail: mpollack@partners.org).

Figure 1. Patients Free of Panic During Paroxetine Treatment^a




^aReprinted with permission from Ballenger et al.¹⁶
*p < .019 vs. placebo.

The selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) have become first-line pharmacotherapy for a number of mood and anxiety disorders, including panic, and have demonstrated efficacy in acute and longer term studies, with paroxetine, fluoxetine, and sertraline receiving U.S. Food and Drug Administration (FDA) approval for the panic disorder indication.^{16,17} A randomized, placebo-controlled, fixed-dose, 10-week trial demonstrated the efficacy of paroxetine for the treatment of panic disorder, with approximately two thirds to three quarters of patients achieving panic-free status by the end of the acute trial (Figure 1).¹⁶

A study examining data from randomized, placebo-controlled studies of sertraline in panic disorder confirmed the efficacy of this SSRI for the condition.¹⁸ It reported greater improvement in quality of life among patients receiving active treatment compared to those taking placebo, even among those who were responders by typical outcome criteria (e.g., panic-free), and affirmed the importance of assessing impact on quality of life in evaluating the effectiveness of treatment interventions (Figure 2). Although not FDA approved for the treatment of panic disorder, other SSRIs, such as escitalopram and citalopram, and SNRIs, such as venlafaxine, have demonstrated efficacy for panic disorder as well.^{19,20}

The SSRIs and SNRIs are effective for many of the comorbidities associated with panic disorder, including depression, social phobia, generalized anxiety disorder, and posttraumatic stress disorder. In addition, they have no abuse or dependence liability and are less likely to negatively interact with alcohol compared to benzodiazepines. However, anxious patients, particularly those with panic disorder, may experience excessive activation, including insomnia, restlessness, jitteriness, agitation, and even exacerbation of panic associated with initiation of SSRIs and SNRIs and other antidepressants. As is true for the tricyclic antidepressants (TCAs) as well, SSRIs

Figure 2. Quality-of-Life Improvement in Sertraline and Placebo Responders^a




^aData from Rapaport et al.¹⁸
^bPairwise comparison of adjusted mean-change scores: *p < .001; †p < .007; ‡p < .003.
Abbreviations: CGI-I = Clinical Global Impressions-Improvement scale, Q-LES-Q = Quality of Life Enjoyment and Satisfaction Questionnaire.

should be initiated at low doses (e.g., 12.5 mg/day of paroxetine controlled release; 25 mg/day of sertraline; 5–10 mg/day of escitalopram; 37.5 mg/day of venlafaxine extended release) in order to minimize increased activation, and then gradually titrated up to therapeutic doses. The SSRIs are associated with less weight gain and fewer anticholinergic effects, have a relatively benign cardiovascular profile, and are safer in overdose compared to the older antidepressants; in addition, they do not have the abuse liability in predisposed individuals associated with benzodiazepines. However, SSRI-associated side effects such as gastrointestinal distress and sexual dysfunction may be problematic for some treated patients, and the delay in time to therapeutic onset (typically at least 2–3 weeks) associated with antidepressant therapy may be problematic for patients requiring more acute anxiolysis.

The TCAs were, for a number of decades, the gold standard in pharmacotherapy for the treatment of panic disorder, but have been largely supplanted by the SSRIs and SNRIs because of their significant side effect burden over the longer term,²¹ substantial toxicity in overdose, and lack of efficacy for some common comorbid disorders such as social phobia.²² Because of its more potent serotonergic properties, some evidence suggests that clomipramine may be the most effective TCA for the treatment of panic disorder.²³ Selective serotonin reuptake inhibitors appear to be at least as efficacious as clomipramine in comparative trials but have a more favorable side effect profile.^{24,25} Side effects are a common cause of treatment failure in TCA-treated patients with panic disorder.²⁶

Monoamine oxidase inhibitors (MAOIs) are also effective for the treatment of panic disorder,²⁷ and although some clinicians believe them to be among the most com-

Figure 3. Pharmacotherapy Received by Panic Disorder Patients in the HARP Study (1989–2001)^a

^aData from Bruce et al.²⁸

Abbreviations: BZD = benzodiazepine, HARP = Harvard/Brown Anxiety Disorders Research Program, SSRIs = selective serotonin reuptake inhibitors.

prehensively effective agents for the treatment of panic and other mood and anxiety disorders, there are no definitive data addressing this issue. Despite their efficacy, the side effect profile of the MAOIs, including associated weight gain, orthostatic hypotension, and sexual dysfunction, along with the requirement of dietary monitoring and the risk of hypertensive crisis, has relegated their use to second or third tier, employed typically after safer and better-tolerated agents have proved ineffective.

BENZODIAZEPINES

Despite increasing emphasis on the use of antidepressants for the treatment of panic and other anxiety disorders, benzodiazepines are still widely used for these conditions. Although data from the Harvard/Brown Anxiety Disorders Research Program documented a small but steady rise in the number of patients getting SSRIs alone and in combination with benzodiazepines through the 1990s into the next decade, the most common type of treatment for patients with panic disorder actually remained benzodiazepine monotherapy (Figure 3).²⁸

Compared to antidepressants, benzodiazepines have a rapid onset of action, favorable side effect profile, and the ability to be used on an “as needed” basis. However, regular use of benzodiazepines is associated with the development of physiologic dependence, necessitating that they be gradually tapered down when discontinued. Unlike antidepressants, benzodiazepines are not effective for the comorbid depression that frequently complicates the presentation of panic and other anxiety disorders. Although individuals predisposed to substance abuse may abuse benzodiazepines, they are very rarely misused in individuals without such a diathesis. Consistent with this assertion are results from a naturalistic study²⁹ examining patterns of benzodiazepine use in over 2000 Medicaid patients receiving these agents for a variety of reasons. The median

dose of benzodiazepine remained constant over 2 years at 10 mg/day of diazepam milligram equivalents, and the incidence of escalation to a high dosage was only 1.6%, suggesting that long-term use of benzodiazepines does not frequently result in notable dose escalation.²⁹

Benzodiazepines are often administered concurrently with antidepressants for the treatment of panic disorder. Although coadministration of a benzodiazepine at treatment initiation accelerates the response compared to antidepressant monotherapy³⁰ and may reduce early antidepressant-related stimulation, combined treatment beyond the first 4 to 6 weeks does not appear to be associated with better outcome by evaluation at 3 months compared to antidepressant monotherapy or patients receiving initial combined treatment followed by taper of the benzodiazepine.³¹ For partial responders and nonresponders to antidepressant monotherapy, the addition of a benzodiazepine to treatment appears to be clinically useful, although there are few systematic data addressing this practice.

OTHER AGENTS

A number of anticonvulsants have demonstrated suggestive evidence of efficacy for panic disorder. In small studies, valproic acid,^{32,33} although not carbamazepine,³⁴ was effective for panic disorder. Gabapentin was significantly effective for panic disorder of moderate severity in a placebo-controlled, double-blind study at doses of 600 to 3600 mg/day.³⁵ Novel anticonvulsants in development or currently available, including pregabalin, tiagabine, and levetiracetam, appear to have anxiolytic effects and may prove effective for the treatment of panic disorder,^{36–38} although formal testing for this indication has not been reported to date. Although bupropion is generally considered ineffective for panic disorder on the basis of an early negative study,³⁹ clinical experience and more re-

cent work⁴⁰ suggest bupropion may have some antipanic efficacy as well.

Some reports suggest that buspirone may be useful as an adjunct to antidepressants and benzodiazepines for the treatment of panic disorder,⁴¹ but it does not appear to be effective when used alone.⁴² Similarly, although useful at times as augmentation, β -blockers (e.g., propranolol) do not appear to be useful as first-line pharmacotherapy for the treatment of panic disorder, although a small, double-blind, placebo-controlled trial suggested the efficacy of augmentation with the β -blocker pindolol (2.5 mg t.i.d.) for patients with panic disorder that is persistently symptomatic despite treatment with fluoxetine.⁴³

LONG-TERM PHARMACOTHERAPY

Most naturalistic studies of panic disorder suggest that it is characterized by a chronic, relapsing course for many patients.^{44,45} Remission rates over time with pharmacotherapy are generally in the range of 20% to 50%, with relapse rates of 25% to 85% after treatment discontinuation.^{46,47} In a study of 51 patients treated to remission with imipramine and then randomized in double-blind fashion to withdrawal of treatment after 6 months versus 12 to 30 months, there was no difference in relapse rates following discontinuation (approximately 37% in both groups). This finding suggests that the critical determinant of persistent benefit following treatment discontinuation may be robustness of improvement before treatment is discontinued rather than duration of treatment.⁴⁸

Although acute treatment and longer term treatment are clearly effective for panic disorder, 30% to 80% of patients continue to experience panic attacks, anticipatory anxiety, and/or avoidance behavior up to 6 years after initiating treatment.^{49,50} Simon and colleagues⁵¹ reported results from a naturalistic study demonstrating that nearly half of patients with panic disorder achieving remission with a variety of pharmacotherapies relapsed within a 24-month follow-up period. Controlled studies examining long-term treatment of panic disorder with SSRIs report rates of relapse of 3% to 13% for patients maintained on treatment for up to 70 weeks.⁵²⁻⁵⁴ However, the relative brevity of study duration and examination of a rarefied clinical trial population limit the applicability of data from these studies. Additional study is necessary to establish the optimal duration of treatment for panic disorder, examine the relative benefit of strategies to optimize response over the maintenance period, and identify patients who may be candidates for successful and sustained discontinuation of therapy.

CONCLUSIONS

A variety of pharmacologic options exist for the treatment of panic disorder. Although antidepressants and

benzodiazepines remain the current mainstay of pharmacotherapy for panic disorder, other novel agents and strategies are becoming available and may add effective alternatives to the therapeutic armamentarium. Maximizing the degree of improvement prior to initiation of treatment discontinuation appears to be a critical determinant in preventing relapse. The relative benefit of different options for the treatment of patients remaining symptomatic despite initial therapy is an issue of critical clinical importance, and further systematic evaluation of this area is warranted.

Drug names: bupropion (Wellbutrin and others), buspirone (BuSpar and others), carbamazepine (Tegretol, Carbatrol, and others), citalopram (Celexa and others), clomipramine (Anafranil and others), diazepam (Valium and others), escitalopram (Lexapro), fluoxetine (Prozac and others), gabapentin (Neurontin and others), imipramine (Tofranil and others), levetiracetam (Keppra), paroxetine (Paxil and others), pindolol (Visken and others), pregabalin (Lyrica), propranolol (Inderal, Innopran, and others), sertraline (Zoloft), tiagabine (Gabitril), valproic acid (Depakene and others), venlafaxine (Effexor).

Disclosure of off-label usage: The author has determined that, to the best of his knowledge, bupropion, buspirone, carbamazepine, citalopram, clomipramine, diazepam, escitalopram, gabapentin, imipramine, pindolol, propranolol, valproic acid, and venlafaxine are not approved by the U.S. Food and Drug Administration for the treatment of panic disorder; and levetiracetam, pregabalin, and tiagabine are not approved for the treatment of anxiety.

REFERENCES

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. *Arch Gen Psychiatry* 1994;51:8-19
2. Pollack MH, Otto MW, Majcher D, et al. Relationship of childhood anxiety to adult panic disorder: correlates and influence on course. *Am J Psychiatry* 1996;153:376-381
3. Manfro GG, Otto MW, McArdle ET, et al. Relationship of antecedent stressful life events to childhood and family history of anxiety and the course of panic disorder. *J Affect Disord* 1996;41:135-139
4. Candilis PJ, McLean RY, Otto MW, et al. Quality of life in patients with panic disorder. *J Nerv Ment Dis* 1999;187:429-434
5. Klerman GL, Weissman MM, Ouellette R, et al. Panic attacks in the community: social morbidity and health care utilization. *JAMA* 1991; 265:742-746
6. Simon GE, VonKorff M. Somatization and psychiatric disorders in the NIMH Epidemiologic Catchment Area study. *Am J Psychiatry* 1991;148: 1494-1500
7. Coryell W, Noyes R, Clancy J. Excess mortality in panic disorder: a comparison with primary unipolar depression. *Arch Gen Psychiatry* 1982;39: 701-703
8. Kawachi I, Sparrow D, Vokonas PS, et al. Symptoms of anxiety and risk of coronary heart disease: the Normative Aging Study. *Circulation* 1994; 90:2225-2229
9. Sartorius N, Ustun TB, Costa e Silva JA, et al. An international study of psychological problems in primary care: preliminary report from the World Health Organization Collaborative Project on Psychological Problems in General Health Care. *Arch Gen Psychiatry* 1993;50:819-824
10. Ormel J, Von Korff M, Ustun TB, et al. Common mental disorders and disability across cultures: results from the WHO Collaborative Study on Psychological Problems in General Health Care. *JAMA* 1994;272: 1741-1748
11. Katon W. Panic disorder and somatization: a review of 55 cases. *Am J Med* 1984;77:101-106
12. Bridges KW, Goldberg DP. Somatic presentation of DSM-III psychiatric disorders in primary care. *J Psychosom Res* 1985;29:563-569

13. Salvador-Carulla L, Segui J, Fernandez-Cano P, et al. Costs and offset effect in panic disorders. *Br J Psychiatry Suppl* 1995;27:23–28
14. Middleton HC, Ashby M. Clinical recovery from panic disorder is associated with evidence of changes in cardiovascular regulation. *Acta Psychiatr Scand* 1995;91:108–113
15. Tucker P, Adamson P, Miranda R Jr, et al. Paroxetine increases heart rate variability in panic disorder. *J Clin Psychopharmacol* 1997;17:370–376
16. Ballenger JC, Wheadon DE, Steiner M, et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. *Am J Psychiatry* 1998;155:36–42
17. Pollack MH, Otto MW, Worthington JJ, et al. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. *Arch Gen Psychiatry* 1998;55:1010–1016
18. Rapaport MH, Pollack M, Wolkow R, et al. Is placebo response the same as drug response in panic disorder? *Am J Psychiatry* 2000;157:1014–1016
19. Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry* 2003;64:1322–1327
20. Pollack MH, Lepola U, Tzanis E, et al. Venlafaxine XR and paroxetine in the short-term treatment of panic disorder. Presented at the 42nd annual meeting of the American College of Neuropsychopharmacology; Dec 7–11, 2003; San Juan, Puerto Rico
21. Noyes R Jr, Perry P. Maintenance treatment with antidepressants in panic disorder. *J Clin Psychiatry* 1990;51(12, suppl A):24–30
22. Emmanuel NP, Lydiard RB, Villareal G. Imipramine in the treatment of social phobia: a double-blind study. Presented at the 36th annual meeting of the American College of Neuropsychopharmacology; Dec 8, 1997; Waikoloa, Hawaii
23. Modigh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo controlled trial. *J Clin Psychopharmacol* 1992;12:251–261
24. den Boer JA, Westenberg HG, Kamerbeek WD, et al. Effect of serotonin uptake inhibitors in anxiety disorders: a double-blind comparison of clomipramine and fluvoxamine. *Int Clin Psychopharmacol* 1987;2:21–32
25. Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. *Acta Psychiatr Scand* 1997;95:153–160
26. Cowley DS, Ha EH, Roy-Byrne PP. Determinants of pharmacologic treatment failure in panic disorder. *J Clin Psychiatry* 1997;58:555–561
27. Sheehan DV, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. *Arch Gen Psychiatry* 1980;37:51–59
28. Bruce SE, Vasile RG, Goisman RM, et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia? *Am J Psychiatry* 2003;160:1432–1438
29. Soumerai SB, Simoni-Wastila L, Singer C, et al. Lack of relationship between long-term use of benzodiazepines and escalation to high dosages. *Psychiatr Serv* 2003;54:1006–1011
30. Goddard AW, Brouette T, Almai A, et al. Early coadministration of clonazepam with sertraline for panic disorder. *Arch Gen Psychiatry* 2001;58:681–686
31. Pollack MH, Simon NM, Worthington JJ, et al. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. *J Psychopharmacol* 2003;17:276–282
32. Woodman CL, Noyes R Jr. Panic disorder: treatment with valproate. *J Clin Psychiatry* 1994;55:134–136
33. Lum M, Fontaine R, Elie R, et al. Divalproex sodium's antipanic effect in panic disorder: a placebo-controlled study. *Biol Psychiatry* 1990;27(suppl 1):164A–165A
34. Uhde TW, Stein MB, Post RM. Lack of efficacy of carbamazepine in the treatment of panic disorder. *Am J Psychiatry* 1988;145:1104–1109
35. Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. *J Clin Psychopharmacol* 2000;20:467–471
36. Simon NM, Worthington JJ, Doyle AC, et al. An open-label study of levetiracetam for the treatment of social anxiety disorder. *J Clin Psychiatry* 2004;65:1219–1222
37. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. *J Clin Psychopharmacol* 2003;23:240–249
38. Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. *J Clin Psychiatry* 2003;64:1245–1249
39. Sheehan DV, Davidson J, Manschreck T, et al. Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. *J Clin Psychopharmacol* 1983;3:28–31
40. Simon NM, Emmanuel N, Ballenger J, et al. Bupropion sustained release for panic disorder. *Psychopharmacol Bull* 2003;37:66–72
41. Gastfriend DR, Rosenbaum JF. Adjunctive buspirone in benzodiazepine treatment of four patients with panic disorder. *Am J Psychiatry* 1989;146:914–916
42. Sheehan DV, Raj AB, Harnett-Sheehan K, et al. The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. *Acta Psychiatr Scand* 1993;88:1–11
43. Hirschmann S, Dannon PN, Iancu I, et al. Pindolol augmentation in patients with treatment-resistant panic disorder: a double-blind, placebo-controlled trial. *J Clin Psychopharmacol* 2000;20:556–559
44. Pollack MH, Marzol PC. Panic: course, complications and treatment of panic disorder. *J Psychopharmacol* 2000;14(suppl 1):S25–S30
45. O'Rourke D, Fahy TJ, Brophy J, et al. The Galway Study of Panic Disorder, 3: outcome at 5 to 6 years. *Br J Psychiatry* 1996;168:462–469
46. Mavissakalian M, Perel JM. Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. *Arch Gen Psychiatry* 1992;49:318–323
47. Rickels K, Schweizer E. Panic disorder: long-term pharmacotherapy and discontinuation. *J Clin Psychopharmacol* 1998;18(suppl 2):12S–18S
48. Mavissakalian MR, Perel JM. Duration of imipramine therapy and relapse in panic disorder with agoraphobia. *J Clin Psychopharmacol* 2002;22:294–299
49. Katschnig H, Amering M, Stolk JM, et al. Predictors of quality of life in a long-term followup study in panic disorder patients after a clinical drug trial. *Psychopharmacol Bull* 1996;32:149–155
50. Roy-Byrne P, Cowley DS. Clinical approach to treatment-resistant panic. In: Rosenbaum JF, Pollack MH, eds. *Panic Disorder and Its Treatment*. New York, NY: Marcel Dekker; 1998:205–228
51. Simon NM, Safren SA, Otto MW, et al. Longitudinal outcome with pharmacotherapy in a naturalistic study of panic disorder. *J Affect Disord* 2002;69:201–208
52. Lydiard RB, Steiner M, Burnham D, et al. Efficacy studies of paroxetine in panic disorder. *Psychopharmacol Bull* 1998;34:175–182
53. Michelson D, Pollack M, Lydiard RB, et al. Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. *Br J Psychiatry* 1999;174:213–218
54. Rapaport MH, Wolkow R, Rubin A, et al. Sertraline treatment of panic disorder: results of a long-term study. *Acta Psychiatr Scand* 2001;104:289–298